PYROXD1

Across TCGA pan-cancer cohorts, PYROXD1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PYROXD1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PYROXD1 RNA is repressed in tumor relative to normal tissue. In most cancer types PYROXD1 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, LIHC, and COAD are the cancer types where PYROXD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PYROXD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.342	<.001	9	view →
LIHC	Male	All	+0.638	<.001	8	view →
COAD	Female	All	−0.686	<.001	7	view →
KICH	All	All	−0.872	<.001	6	view →
KIRP	Male	All	−0.668	<.001	6	view →
CHOL	Male	All	+1.185	<.001	5	view →
UCEC	All	IV	−1.020	.008	2	view →
LUAD	Female	II,III,IV	−0.403	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PYROXD1–THCA

Open the THCA breakdown →